Tharindumala Abeywardana

Tharindumala Abeywardana

Auto-generated profile, based on publicly available information

Tharindumala Abeywardana

Moores Cancer Center, UC San Diego, La Jolla, California

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FMFranziska Meier
Franziska Meier
TATharindumala Abeywardana
Tharindumala Abeywardana
ADAbhinav Dhall
Abhinav Dhall
NMNicholas P. Marotta
Nicholas P. Marotta
JVJobin Varkey
Jobin Varkey
MPMatthew Pratt
Matthew Pratt

9 March 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
WDWenting Dai
Wenting Dai
GWGuan Wang
Guan Wang
JCJason Shin Chwa
Jason Shin Chwa
MOMyung Eun Oh
Myung Eun Oh
TATharindumala Abeywardana
Tharindumala Abeywardana
LJLei Jiang
Lei Jiang
Background: Previous studies suggested that mdivi-1 (mitochondrial division inhibitor), a putative inhibitor of dynamin-related protein (DRP1), decreased cancer cell proliferation through inducing mitochondrial fusion and altering oxygen consumption. However, the metabolic reprogramming underlying the DRP1 inhibition is still unclear in cancer cells. Methods: To better understand the metabolic effect of DRP1 inhibition, [U-13C]glucose isotope tracing was employed to assess mdivi-1 effects in several cancer cell lines, DRP1-WT (wild-type) and DRP1-KO (knockout) H460 lung cancer cells and mouse embryonic fibroblasts (MEFs). Results: Mitochondrial staining confirmed that mdivi-1 treatment and DRP1 deficiency induced mitochondrial fusion. Surprisingly, metabolic isotope tracing found that mdivi-1 decreased mitochondrial oxidative metabolism in the lung cancer cell lines H460, A549 and the colon cancer cell line HCT116. [U-13C]glucose tracing studies also showed that the TCA cycle intermediates had significantly lower enrichment in mdivi-1-treated cells. In comparison, DRP1-WT and DRP1-KO H460 cells had similar oxidative metabolism, which was decreased by mdivi-1 treatment. Furthermore, mdivi-1-mediated effects on oxidative metabolism were independent of mitochondrial fusion. Conclusions: Our data suggest that, in cancer cells, mdivi-1, a putative inhibitor of DRP1, decreases oxidative metabolism to impair cell proliferation.


9 November 2012 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
NMNicholas P. Marotta
Nicholas P. Marotta
CCCarli A. Cherwien
Carli A. Cherwien
TATharindumala Abeywardana
Tharindumala Abeywardana
MPMatthew Pratt
Matthew Pratt

1 October 2013 in Chemistry & Biology
Verified
Journal Article
Closed access
TATharindumala Abeywardana
Tharindumala Abeywardana
YLYu Hsuan Lin
Yu Hsuan Lin
RRRuth Rott
Ruth Rott
SESimone Engelender
Simone Engelender
MPMatthew Pratt
Matthew Pratt

1 September 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TATharindumala Abeywardana
Tharindumala Abeywardana
MOMyungeun Oh
Myungeun Oh
LJLei Jiang
Lei Jiang
YYYing Yang
Ying Yang
MKMei Kong
Mei Kong
YYYanzhong Yang
Yanzhong Yang
Glucose is a critical nutrient for cell proliferation. However, the molecular pathways that regulate glucose metabolism are still elusive. We discovered that coactivator-associated arginine methylatransferase 1 (CARM1) suppresses glucose metabolism towards serine biosynthesis. By tracing the 13C-labeled glucose, we found that Carm1 knockout mouse embryonic fibroblasts (MEFs) exhibit significantly increased de novo serine synthesis than wild type cells. This is caused, at least in part, by the reduced pyruvate kinase (PK) activity in these cells. The M2 isoform of PK (PKM2) is arginine methylated by Carm1 and methylation enhances its activity. Mechanistically, Carm1 methylates PKM2 at arginine R445 and R447, which enhances PKM2 tetramer formation. Consequently, Carm1 knockout cells exhibit significant survival advantages over wild type cells when extracellular serine is limited, likely due to their enhanced de novo serine synthesis capacity. Altogether, we identified CARM1 as an important regulator of glucose metabolism and serine synthesis.